Dengue nucleic acid vaccines that induce neutralizing antibodies
US6455509B1 · kind B1 · utility
28Cited by
1References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 4, 1997 |
| Grant date | Sep 24, 2002 |
| Priority date | — |
| Expiry date | Jun 4, 2017 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A vaccine for promoting an immune response in a mammalian subject includes a eucaryotic plasmid expression vector which include at least part of the envelope gene and optionally, the PreM gene of dengue virus. In order to minimize immune enhancement, vaccines of up to the four serotypes of dengue are combined in a single vaccine. The vaccine in a suitable pharmaceutical carrier constitutes a pharmaceutical composition which is injected into the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.